Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
Johnson and Johnson
Merck
Harvard Business School

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR CITALOPRAM HYDROBROMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Citalopram Hydrobromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00086645 ↗ Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed National Institute of Mental Health (NIMH) Phase 2 2004-04-01 This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.
NCT00086645 ↗ Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed Boston University Phase 2 2004-04-01 This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.
NCT00222820 ↗ Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed Mental Health Intervention Research Center (MHIRC) Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person's personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00222820 ↗ Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed University of Pittsburgh Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person's personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00363909 ↗ Citalopram in Treating Postmenopausal Women With Hot Flashes Completed National Cancer Institute (NCI) Phase 3 2006-11-01 RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram to compare how well they work in treating postmenopausal women with hot flashes.
NCT00363909 ↗ Citalopram in Treating Postmenopausal Women With Hot Flashes Completed Alliance for Clinical Trials in Oncology Phase 3 2006-11-01 RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram to compare how well they work in treating postmenopausal women with hot flashes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Citalopram Hydrobromide

Condition Name

Condition Name for Citalopram Hydrobromide
Intervention Trials
Healthy 5
Psychosocial Effects of Cancer and Its Treatment 2
Breast Cancer 2
Depression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Citalopram Hydrobromide
Intervention Trials
Depression 4
Depressive Disorder 3
Hot Flashes 2
Depressive Disorder, Major 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Citalopram Hydrobromide

Trials by Country

Trials by Country for Citalopram Hydrobromide
Location Trials
United States 46
India 2
Canada 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Citalopram Hydrobromide
Location Trials
Pennsylvania 3
Indiana 2
Oklahoma 2
California 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Citalopram Hydrobromide

Clinical Trial Phase

Clinical Trial Phase for Citalopram Hydrobromide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Citalopram Hydrobromide
Clinical Trial Phase Trials
Completed 9
Recruiting 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Citalopram Hydrobromide

Sponsor Name

Sponsor Name for Citalopram Hydrobromide
Sponsor Trials
Torrent Pharmaceuticals Limited 2
Dr. Reddy's Laboratories Limited 2
National Institute of Mental Health (NIMH) 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Citalopram Hydrobromide
Sponsor Trials
Other 8
Industry 6
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Merck
McKesson
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.